A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
Public ClinicalTrials.gov record NCT06295809. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant Intismeran Autogene (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007)
Study identification
- NCT ID
- NCT06295809
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Interventions
- Intismeran autogene Biological
- Pembrolizumab Biological
- Surgery Procedure
Biological · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 17, 2024
- Primary completion
- Mar 4, 2026
- Completion
- Mar 4, 2026
- Last update posted
- May 7, 2026
2024 – 2026
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC/Norris Comprehensive Cancer Center ( Site 1112) | Los Angeles | California | 90033 | — |
| Hoag Memorial Hospital Presbyterian ( Site 1122) | Newport Beach | California | 92663 | — |
| Stanford Cancer Center ( Site 1109) | Palo Alto | California | 94304 | — |
| University of California Davis (UC Davis) Comprehensive Cancer Center ( Site 1103) | Sacramento | California | 95817 | — |
| Winship Cancer Institute, Emory University ( Site 1151) | Atlanta | Georgia | 30322 | — |
| University of Iowa-Holden Comprehensive Cancer Center ( Site 1118) | Iowa City | Iowa | 52242 | — |
| University of Kentucky Chandler Medical Center ( Site 1101) | Lexington | Kentucky | 40536 | — |
| Ochsner Clinic Foundation ( Site 1113) | New Orleans | Louisiana | 70121 | — |
| Massachusetts General Hospital ( Site 1162) | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute ( Site 1130) | Boston | Massachusetts | 02215 | — |
| Washington University School of Medicine-Internal Medicine/Oncology ( Site 1100) | St Louis | Missouri | 63110 | — |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 1125) | Hackensack | New Jersey | 07601 | — |
| Atlantic Health System Morristown Medical Center ( Site 1136) | Morristown | New Jersey | 07960 | — |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 1160) | Mineola | New York | 11501 | — |
| Laura and Isaac Perlmutter Cancer Center ( Site 1121) | New York | New York | 10016 | — |
| Providence Portland Medical Center ( Site 1102) | Portland | Oregon | 97213 | — |
| UPMC Hillman Cancer Center ( Site 1107) | Pittsburgh | Pennsylvania | 15232 | — |
| Avera Cancer Institute- Research ( Site 1161) | Sioux Falls | South Dakota | 57105 | — |
| University of Virginia Health System ( Site 1115) | Charlottesville | Virginia | 22908 | — |
| Inova Schar Cancer Institute ( Site 1108) | Fairfax | Virginia | 22031 | — |
| University Hospital and UW Health Clinics ( Site 1119) | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 85 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06295809, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06295809 live on ClinicalTrials.gov.